Register  /  Login               

Cerbios-Pharma – Moving along with ADCs: a CDMO perspective

e-version image

Click HERE to download the PDF version


Antibody-drug conjugates (ADCs) for oncology therapies are composed of an antibody chemically conjugated to a highly potent cytotoxic drug through a specific linker molecule. Currently, ADCs together with gene therapy CAR-Ts represent, in terms of the number of clinical trials, the fastest growing and most promising products in oncology. It is, therefore, not surprising that nearly 40% of antibody-based therapies for cancer therapy in late-stage development are ADCs or similar products.

It is worth underlining the diversity of the payloads present in the ADCs in Phase III; two products have a previously approved toxin (MMAE) targeting microtubules, while the remaining have seven new payloads including PBD dimers, duocarmicins, topoisomerase I inhibitors and radionuclides.

The high number of ADCs in late development is fo ... ...

About us

tks | publisher, event organiser,
media agency

Viale Brianza, 22
20127 - Milano - Italy
Tel. +39 02 26809375